Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial-Reference-Cited by-同舟云学术

Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial

Published:2024-08 Issue:8 Volume:25 Page:1092-1102
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Liu Xin,Zhang Xiaowei,Jiang Shiyu,Mo Miao,Wang Qifeng,Wang Yanli,Zhou Liangping,Hu Silong,Yang Huijuan,Hou Yifeng,Chen Yong,Lu Xueguan,Wang Yu,Zhou Xiaoyan,Li Wentao,Chang Cai,Yang Xiujiang,Chen Ke,Cao Jun,Xu Qinghua,Sun Yifeng,Luo Jianfeng,Luo Zhiguo,Hu Xichun

Publisher

Elsevier BV

Reference31 articles.

1. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Krämer;Ann Oncol,2023

2. Descriptive epidemiology of cancer of unknown primary site in Scotland, 1961-2010;Brewster;Cancer Epidemiol,2014

3. Cancer of unknown primary in the molecular era;Kato;Trends Cancer,2021

4. Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?;Olivier;Cancer Treat Rev,2021

5. SEOM-GECOD clinical guideline for unknown primary cancer (2021);Losa;Clin Transl Oncol,2022

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New clinical trials in CUP and a novel paradigm in cancer classification;Nature Reviews Clinical Oncology;2024-09-11

2. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study;The Lancet;2024-08

3. Molecular diagnosis and site-specific therapy in cancer of unknown primary: an important milestone;The Lancet Oncology;2024-08